Single answer
Is Akero Therapeutics Inc (AKRO) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
$1 invested is now $1.17 or 17.21%
(In 48 weeks 1 day 22 hours 48 minutes and 26 seconds .)
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Akero Therapeutics Inc is $54.67, which is $0.0200 (0.04%) above the current price today's price.
Low target: $54.00 | High target: $56.00
Company snapshot
A quick overview of the business and its public profile.
Akero Therapeutics Inc a cardiometabolic nonalcoholic steatohepatitis NASH company engages in the development of medicines designed to restore metabolic balance and improve overall health The companys lead product candidate is efruxifermin EFX an analog of fibroblast growth factor 21 which protects against cellular stress and regulates metabolism of lipids carbohydrates and proteins throughout the body It also conducts a Phase 2a clinical trial the BALANCED study to evaluate EFX in the treatment of biopsyconfirmed NASH patients The company was formerly known as Pippin Pharmaceuticals Inc and changed its name to Akero Therapeutics Inc in May 2018 Akero Therapeutics Inc was incorporated in 2017 and is headquartered in South San Francisco California
Website: https://www.akerotx.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.03. Cash flow to debt ratio: -6.81. Net profit margin: -7,098,980.00%. Inflation risk score: medium (0.70/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Akero Therapeutics Inc is $109.4M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Akero Therapeutics Inc 10 years ago, but if you had invested on 2019-06-20 when the price was $18.32, you would have made a profit of $36.33 per share or 198.31%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.